Profil
Søren Gade Jensen is currently the Chairman of Tecleaf ApS, Director of Samfonden, and Director of Fulton Foundation.
He previously served as an Independent Director for Allarity Therapeutics A and is set to serve as an Independent Director for Allarity Therapeutics, Inc. from 2021 to 2023.
He graduated from the University of Aarhus.
Postes actifs de Søren Gade Jensen
| Sociétés | Poste | Début |
|---|---|---|
| Tecleaf ApS | Chairman | - |
| Samfonden | Director/Board Member | - |
| Fulton Foundation | Director/Board Member | - |
Anciens postes connus de Søren Gade Jensen
| Sociétés | Poste | Fin |
|---|---|---|
| ALLARITY THERAPEUTICS, INC. | Director/Board Member | 04/02/2023 |
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Director/Board Member | - |
Formation de Søren Gade Jensen
| University of Aarhus | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALLARITY THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Health Technology |
| Tecleaf ApS | |
| Samfonden | |
| Fulton Foundation |
